Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 10/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LIPE | Q05469 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5112014 | 0.86 | SCN9A (0.49) | LMNASCN9ASCN10A | |
| SCHEMBL5112029 | 0.86 | SCN9A (0.49) | LMNASCN9ASCN10A | |
| SCHEMBL3204732 | 0.83 | LMNA (0.52) | LMNAHPGDSMN1; SMN2ALDH1A1LIPE | |
| SCHEMBL5113718 | 0.78 | MAPK1 (0.45) | MAPK1LMNASCN9AHPGDSCN10A | |
| SCHEMBL8027838 | 0.76 | THRB (0.54) | MAPK1LMNASCN9ASCN10AALDH1A1 | |
| SCHEMBL22090747 | 0.75 | POLB (0.41) | HPGDSMN1; SMN2ALDH1A1POLBL3MBTL1 | |
| SCHEMBL5121147 | 0.75 | MAPK1 (0.45) | MAPK1LMNASCN9AHPGDSCN10A | |
| SCHEMBL3200445 | 0.75 | ALDH1A1 (0.56) | LMNAHPGDSMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL3905573 | 0.73 | ALDH1A1 (0.69) | LMNATSHRALDH1A1POLBL3MBTL1 | |
| SCHEMBL3215665 | 0.73 | PPARG (0.61) | LMNAHPGDSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | MAPK1 2249/4885LMNA 3761/4885SCN9A 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.